Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE healthy aging polytherapy pilot
ISRCTN84791030Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in healthy aging and None comparing Metformin + semaglutide + AB-01 + AB-02 with Metformin + empagliflozin + AB-01 + AB-02 (2 arms). Primary endpoint: Muscular-Immune-Cognitive Composite score. Started Nov 2025; status: completed.
02
Drugs
03
Conditions
healthy aging
Beyond the preview
Go deeper on ISRCTN84791030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84791030.